Folic Acid-Modified Cyclodextrin Composition for Selective Tumor Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for advanced cancers, are inadequate, and there is a need for more effective treatments that can selectively target cancer cells while minimizing impact on normal cells.
Innovation Solution
A pharmaceutical composition is developed using folic acid-appended hydroxyalkylated cyclodextrins, which enhance tropism to high folate receptor-expressing tumor cells, thereby increasing anticancer action and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then anticancer effect is achieved, but selectivity between cancer cells and normal cells is insufficient
Solution Approach 1:
The cyclodextrin molecule is modified with folic acid at specific positions to create a localized targeting function. The folic acid moiety specifically binds to folate receptors on cancer cells, while the cyclodextrin core maintains its cholesterol-binding capability, creating a dual-functional molecule with spatially differentiated properties
Solution Approach 2:
Folic acid acts as an intermediary ligand that mediates the interaction between the cyclodextrin carrier and the folate receptor on cancer cells. This intermediary enables selective recognition and binding to target cells, bridging the gap between the carrier system and the target cells
2Reliability
If cyclodextrin is used to extract cholesterol from lipid rafts, then antitumor action is achieved, but cellular uptake efficiency is insufficient
Solution Approach 1:
Folic acid is pre-attached to the cyclodextrin molecule before administration, creating a pre-formed conjugate that is immediately ready for receptor-mediated endocytosis upon contact with cancer cells, eliminating the need for separate ligand attachment steps
Solution Approach 2:
The molecular structure of cyclodextrin is chemically modified by introducing folic acid groups, changing its biological recognition parameters. This structural modification enables the molecule to be recognized by folate receptors, fundamentally altering its cellular interaction properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition exhibits a stronger anticancer effect, demonstrated by enhanced cellular uptake and apoptosis induction in leukemia cells, leading to prolonged survival times in mouse models, with potential for reduced side effects due to targeted delivery.
Implementation Method 1
the folate receptor (FR) is overexpressed in various epithelial cancer cells and exhibits low expression in normal cells, which, as a result, enables selective uptake by cancer cells via FR-mediated endocytosis
Implementation Method 2
Cyclodextrin (CyD) is a cyclic maltooligosaccharide, in which glucose is connected by α-1,4-bonds, and is a monomolecular host molecule capable of incorporating, in a hydrophobic cavity thereof, various drugs
Implementation Method 3
CyD tightly binds cholesterol and is widely used as a raft inhibitor because CyD extracts cholesterol from lipid rafts in a cell membrane and thereby disrupts a structure thereof
Data Source
AI summary
Provided herein is a pharmaceutical composition for treating cancer, the pharmaceutical composition containing: a folic acid-modified hydroxyalkylated cyclodextrin selected from the group consisting of folic acid-modified hydroxypropylcyclodextrin, folic acid-modified hydroxybutylcyclodextrin, and folic acid-modified hydroxyethyl cyclodextrin; or a derivative thereof. Thus, a novel pharmaceutical composition for treating cancer and the like is provided.